Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class…

NOVATO, Calif., Feb 04, 2010 /PRNewswire via COMTEX/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.